60 DEGREES PHARMACEUTICALS, INC. (SXTP): Nasdaq/NYSE listing notice — 60 Degrees Pharmaceuticals receives Nasdaq deficiency notice for bid price non-compliance

60 DEGREES PHARMACEUTICALS, INC.

On Nov 2, 2023, Nasdaq notified SXTP that its common stock failed to maintain minimum $1.00 closing bid price for 30 consecutive business days through Nov 1, 2023.
The company has a 180-day compliance period until April 30, 2024 to regain compliance with the Bid Price Rule.
If not compliant by April 30, 2024, SXTP may be eligible for an additional 180-day period if it meets other listing standards.
Failure to regain compliance may result in delisting of common stock and warrants from Nasdaq Capital Market.
The company is evaluating options to regain compliance, including potential reverse stock split.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

60 DEGREES PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

arket pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

60 DEGREES PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-083513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.